Thursday , December 9 2021

The crown vaccine begins on that date



[ad_1]

He said: We will apply for a license “very soon”

Pfizer CEO Albert Burla announced yesterday, Tuesday, that the U.S. pharmaceutical group will “very soon” apply for a license to market a vaccine against Corona in the United States, which will allow, if all goes well, the vaccine to begin in December.

“We are very close to submitting an emergency license application,” Burlak said at a conference hosted by the Statenews website.

The CEO of Pfizer has not confirmed or denied whether the application will be submitted this week, and stated earlier that he said the application would be submitted in the third week of November, according to the “French”.

Pfizer has developed this experimental vaccine in collaboration with the German company Biontech.

An emergency license is a temporary or conditional permit issued by the U.S. Medicines Agency (FDA) to deal with emergencies such as the Corona pandemic.

The Agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine appear later.

The U.S. Food and Drug Administration did not mention how long it would take to review vaccine efficacy and safety data, which are the two main criteria for obtaining emergency licenses, in addition to the ability to produce large doses.

The Pfizer vaccine is one of three experimental vaccines that the European Medicines Agency continues to conduct in clinical trials, according to its rapid mechanism.

The other two vaccines have evolved: Oxford AstraZeneca and Modirna.

American company Pfizer, the new Crown virus

Pfizer has announced that vaccination against the Crown has begun on this date


Before

Albert Burla, CEO of Pfizer, announced yesterday, Tuesday, that the U.S. pharmaceutical group will “very soon” apply for a license to market a vaccine against Corona in the United States, which if all goes well, will start vaccination next December.

“We are very close to applying for an emergency license,” Burlak said at a conference hosted by the Statenews website.

The CEO of Pfizer did not confirm or deny that the application would be submitted this week, and said he had previously said the application would be submitted in the third week of November, according to the “French”.

Pfizer has developed this experimental vaccine in collaboration with the German company Biontech.

An emergency license is issued by the U.S. Medicines Agency, “FDA,” as a temporary or conditional permit to deal with emergencies such as the Corona pandemic.

The Agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine appear.

The U.S. Food and Drug Administration did not mention how long it would take to review vaccine efficacy and safety data, which are the two main criteria for obtaining emergency licenses, in addition to the ability to produce large doses.

The Pfizer vaccine is one of three experimental vaccines that the European Medicines Agency continues to conduct in clinical trials, according to its rapid mechanism.

The other two vaccines have evolved: Oxford AstraZeneca and Modirna.

November 18, 2020 – Rabbi Al-Thani 3 1442

10:26


He said: We will apply for a license “very soon”

Pfizer CEO Albert Burla announced yesterday, Tuesday, that the U.S. pharmaceutical group will “very soon” apply for a license to market a vaccine against Corona in the United States, which will allow, if all goes well, the vaccine to begin in December.

“We are very close to applying for an emergency license,” Burlak said at a conference hosted by the Statenews website.

The CEO of Pfizer has not confirmed or denied whether the application will be submitted this week, and said he had previously said the application would be submitted in the third week of November, according to the “French”.

Pfizer has developed this experimental vaccine in collaboration with the German company Biontech.

An emergency license is a temporary or conditional authorization from the U.S. Medicines Agency, “FDA,” to deal with emergencies such as the Corona pandemic.

The Agency may revoke or modify this authorization if new data on the efficacy or safety of the vaccine appear later.

The U.S. Food and Drug Administration did not mention how long it would take to review vaccine efficacy and safety data, which are the two main criteria for obtaining emergency licenses, in addition to the ability to produce large doses.

The Pfizer vaccine is one of three experimental vaccines that the European Medicines Agency continues to conduct in clinical trials, according to its rapid mechanism.

The other two vaccines have evolved: Oxford AstraZeneca and Modirna.



[ad_2]
Source link